Repotrectinib/CYP3A4 Inhibitors and Substrates Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Your other medicine may slow down how quickly your body processes repotrectinib and repotrectinib may speed up how quickly your body processes your other medicine.

What might happen:

The amount of repotrectinib in your blood may increase and cause more side effects than usual, including central nervous system effects, lung problems, muscle problems, and liver injury. The amount of your other medicine may decrease and may not work as well.

What you should do about this interaction:

Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicines.Let your doctor know right away if you develop dizziness, mood changes, trouble with coordination, memory problems, confusion, hallucinations, loss of appetite, nausea or vomiting, yellowish eyes or skin, dark urine, light-colored stools, right abdominal pain, or unexplained muscle pain that does not go away. Tell your doctor if you have new or worsening cough, wheezing or trouble breathing.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Augtyro (repotrectinib) US prescribing information. Bristol-Myers Squibb Company November, 2023.
  • 2.Voquezna (vonoprazan-amoxicillin and vonoprazan-amoxicillin-clarithromycin) US prescribing information. Phathom Pharmaceuticals, Inc. November, 2023.
  • 3.Zydelig (idelalisib) US prescribing information. Gilead Sciences, Inc. October, 2020.
  • 4.Xalkori (crizotinib) US prescribing information. Pfizer Inc. September, 2023.
  • 5.Copiktra (duvelisib) US prescribing information. Verastem, Inc. December, 2021.
  • 6.Inrebic (fedratinib) US prescribing information. Impact Biomedicines, Inc May, 2023.
  • 7.Xenleta (lefamulin) US Prescribing information. Nabriva Therapeutics US, Inc August 2019.
  • 8.Sunlenca (lenacapavir) US prescribing information. Gilead Sciences, Inc. December, 2022.
  • 9.Oxbryta (voxelotor) US prescribing information. Global Blood Therapeutics, Inc. December, 2021.
  • 10.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.